Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1996-06-28
1998-12-01
Spivack, Phyllis G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514189, A61K 31555
Patent
active
058439366
ABSTRACT:
A locally administrable topical pharmaceutical composition is provided for use in the prevention or treatment of skin conditions associated with hyperproliferation of keratinocytes and/or an immunologically mediated disorders, as psoriasis, atopic dermatitis, contact dermatitis, seborrheic dermatitis or actinic dermatitis. The composition contains a topical carrier and spirogermanium or a structurally related azaspirane.
REFERENCES:
patent: 3825546 (1974-07-01), Rice
patent: 4291030 (1981-09-01), Mulinos
patent: 4468393 (1984-08-01), Geschickter
patent: 4654333 (1987-03-01), Tenoso
patent: 5064835 (1991-11-01), Bochis et al.
Goodwin et al., Cancer Treatment Reports, 71 (10)985-6 (1987 Oct.).
Jack L. Arbiser (1996), "Angiogenesis and the Skin: a Primer," J. Am Acad Dermatol U.S., 34(3):486-497.
Alison M. Badger et al. (1990), "Antiarthritic and Suppressor Cell Inducing Activity of Azaspiranes: Structure-Function Relationships of a Novel Class of Immunomodulatory Agents," J. Med. Chem. 33:2963-2970.
Elizabeth Eisenhauer et al. (1985), "A Phase II Study of Spirogermanium in Patients with Metastatic Malignant Melanoma," Investigational New Drugs 3:303-305.
Bridget T. Hill et al (1982), "Cytotoxic Effects and Biological Activity of Dichloride (NSC 192965; Spirogermanium) in Vitro," Cancer Research 42(7):2852-2856.
Daniel N. Sauder et al. (1980), "Suppressor Cell Function in Psoriasis," Arch. Dermatol. 116: 51-55.
Schein, P.S., et al., "Phase I Clinical Trial of Spirogermanium," Cancer Treatment Reports, vol. 64, No. 10-11, pp. 1051-1056 (Oct./Nov. 1980).
Badger et al., "Generation of Suppressor Cells in Normal Rats by Treatment with Spirogermanium, a Novel Heterocyclic Anticancer Drug," Immunopharmacology 10:201-207 (1985).
Badger et al., "Antiarthritic and Suppressor Cell Inducing Activity of Azaspiranes: Structure-Function Relationships of a Novel Class of Immunomodulatory Agents," J. Med. Chem. 33:2963-2970 (1990).
Berardesca et al., "Non-invasive Evaluation of Topical Calcipotriol versus Clobetasol in the Treatment of Psoriasis," Acta Derm Venereol (Stokh) 74:302-304 (1994).
DiMartino et al., "Antiarthritic and Immunoregulatory Activity of Spirogermanium," J. Pharmacol. and Exper. Therapeutics 236(1):103-110.
Elias et al., "A Controlled Trial of Topical Propylthiouracil in the Treatment of Patients with Psoriasis," J. Amer. Acad. Dermatol. 31(3):455-458.
Highton et al., "Calcipotriene Ointment 0.005% for Psoriasis: A Safety and Efficacy Study," J. Amer. Acad. Dermatol. 32(1):67-72 (1995).
Mirabelli et al., "Pharmacological Activities of Spirogermanium and Other Structurally Related Azaspiranes: Effects on Tumor Cell and Macrophage Functions," Anti-Cancer Drug Design 3:231-242 (1989).
Rice et al., "Spirans XXII. Synthesis of 4,4-Dialkyl-4-germacyclo-hexanone 11:1041-1047 (1974).
Slavik et al., "Spirogermanium: A New Investigational Drug of Novel Structure and Lack of Bone Marrow Toxicity," Investigational New Drugs 1:225-234 (1983).
Maher David W.
Reed Dianne E.
Spivack Phyllis G.
LandOfFree
Topical administration of azaspiranes to prevent or treat skin c does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Topical administration of azaspiranes to prevent or treat skin c, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Topical administration of azaspiranes to prevent or treat skin c will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2395776